Outcomes of Coronary Artery Bypass Grafting in Israeli Jews and Arabs

January 3, 2025 updated by: Dror B. Leviner, Technion, Israel Institute of Technology
Retrospective study of adult patients with multivessel disease undergoing isolated CABG in three centers between January 1st, 2009, and December 31st, 2023. The primary outcome was a composite of major adverse cardiac and cerebrovascular events (MACCE). Patients were grouped according to their ethnic origin, Arabs and Jews.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

7067

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients undergoing isolated CABG at Carmel medical center, Beilinson medical center and Soroka medical center at Israel

Description

Inclusion Criteria:

  • isolated CABG

Exclusion Criteria:

  • members of different HMO

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Arab ethnicity
All Arab patients undergoing isolated CABG
Procedure: CABG
All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
Jew ethnicity
All Jew patients undergoing isolated CABG
Procedure: CABG
All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
MACCE
Time Frame: through study completion, a median of 78 months
through study completion, a median of 78 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Mortality
Time Frame: through study completion, a median of 78 months
through study completion, a median of 78 months
MI
Time Frame: through study completion, a median of 78 months
through study completion, a median of 78 months
CVA
Time Frame: through study completion, a median of 78 months
through study completion, a median of 78 months
repeat revascularization
Time Frame: through study completion, a median of 78 months
through study completion, a median of 78 months
utilization of multi-arterial grafting
Time Frame: through study completion, a median of 78 months
through study completion, a median of 78 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Technion, Israel Institute of Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2009

Primary Completion (Actual)

December 31, 2023

Study Completion (Actual)

December 31, 2023

Study Registration Dates

First Submitted

December 27, 2024

First Submitted That Met QC Criteria

January 3, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 3, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • CMC 21-175

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe